紅寶麗(002165.SZ):環氧丙烷項目正在進行技術改造,還未生產
格隆匯4月17日丨紅寶麗(002165.SZ)公佈股票交易異常波動公告,公司環氧丙烷項目正在進行技術改造,還未生產,目前環氧丙烷未形成銷售收入,對公司業績沒有影響。公司環氧丙烷綜合技術改造項目進展情況:該技改項目已完成職業病危害預評價,已取得環評批覆、能評批覆、安評批覆以及完成總平面圖審查等手續辦理工作。同時,項目已完成了工藝包設計、初步設計,土建結構、設備佈置、工藝管道及儀表等詳細設計工作基本完成;老裝置加固工程取得施工許可證,並完成相應加固工程施工;設備與材料採購完成,設備已陸續交貨進場,等等,項目建設在抓緊推進中。項目預計於2025年底進入試生產階段。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.